Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome

Human Molecular Genetics

Volumn 16, Issue 5, 2007, Pages 515-528

  Rodgers, Kathryn D ^a   Sasaki, Takako ^b   Aszodi, Attila ^b   Jacenko, Olena ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYSTEINE; GLYCINE; PERLECAN; PROTEOHEPARAN SULFATE; PROTEOHEPARAN SULFATE 4; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERALIZATION; BONE NECROSIS; CELL STRAIN 3T3; CELL STRAIN HEK293; CHONDRODYSPLASIA; CONTROLLED STUDY; DWARFISM; FACE DYSMORPHIA; GENE MUTATION; GROWTH PLATE; HIP DYSPLASIA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NEWBORN; NONHUMAN; OSTEOARTHRITIS; PHENOTYPE; PIGEON THORAX; PRIORITY JOURNAL; SCHWARTZ JAMPEL SYNDROME; TRABECULAR BONE; TRANSCRIPTION REGULATION;

ANIMALS; ANIMALS, NEWBORN; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MALE; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTANT PROTEINS; MUTATION; NEOMYCIN; NIH 3T3 CELLS; OSTEOCHONDRODYSPLASIAS; PHENOTYPE; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

MUS;

EID: 34047097475     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddl484     Document Type: Article

References (48)

1. Dziadek, M., Fujiwara, S., Paulsson, M. and Timpl, R. (1985) Immunological characterization of basement membrane types of heparan sulfate proteoglycan. EMBO J., 4, 905-912.
2. French, M.M., Smith, S.E., Akanbi, K., Sanford, T., Hecht, J., Farach-Carson, M.C. and Carson, D.D. (1999) Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J. Cell Biol., 145, 1103-1115.
3. Handler, M., Yurchenco, P.D. and Iozzo, R.V. (1997) Developmental expression of perlecan during murine embryogenesis. Dev. Dyn., 210, 130-145.
4. Hassell, J.R., Robey, P.G., Barrach, H.J., Wilczek, J., Rennard, S.I. and Martin, G.R. (1980) Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc. Natl Acad. Sci. USA, 77, 4494-4498.
5. Govindraj, P., West, L., Koob, T.J., Neame, P., Doege, K. and Hassell, J.R. (2002) Isolation and identification of the major heparan sulfate proteoglycans in the developing bovine rib growth plate. J. Biol. Chem., 277, 19461-19469.
6. Iozzo, R.V., Cohen, I.R., Grassel, S. and Murdoch, A.D. (1994) The biology of perlecan: The multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem. J., 302(Pt 3), 625-639.
7. Melrose, J., Smith, S., Cake, M., Read, R. and Whitelock, J. (2005) Perlecan displays variable spatial and temporal immunolocalisation patterns in the articular and growth plate cartilages of the ovine stifle joint. Histochem. Cell Biol., 123, 561-571.
8. Klein, G., Conzelmann, S., Beck, S., Timpl, R. and Muller, C.A. (1995) Perlecan in human bone marrow: A growth-factor-presenting, but anti-adhesive, extracellular matrix component for hematopoietic cells. Matrix Biol., 14, 457-465.
9. Noonan, D.M. and Hassell, J.R. (1993) Perlecan, the large low-density proteoglycan of basement membranes: Structure and variant forms. Kidney Int., 43, 53-60.
10. Arikawa-Hirasawa, E., Le, A.H., Nishino, I., Nonaka, I., Ho, N.C., Francomano, C.A., Govindraj, P., Hassell, J.R., Devaney, J.M., Spranger, J. et al. (2002) Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am. J. Hum. Genet., 70, 1368-1375.
11. Arikawa-Hirasawa, E., Wilcox, W.R., Le, A.H., Silverman, N.,Govindraj, P., Hassell, J.R. and Yamada, Y. (2001) Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat. Genet., 27, 431-434.
12. Timpl, R. (1993) Proteoglycans of basement membranes. Experientia, 49, 417-428.
13. Dolan, M., Horchar, T., Rigatti, B. and Hassell, J.R. (1997) Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J. Biol. Chem., 272, 4316-4322.
14. Friedrich, M.V., Gohring, W., Morgelin, M., Brancaccio, A., David, G. and Timpl, R. (1999) Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J. Mol. Biol., 294, 259-270.
15. Knox, S., Fosang, A.J., Last, K., Melrose, J. and Whitelock, J. (2005) Perlecan from human epithelial cells is a hybrid heparan/chondroitin/ keratan sulfate proteoglycan. FEBS Lett., 579, 5019-5023.
16. Arikawa-Hirasawa, E., Watanabe, H., Takami, H., Hassell, J.R. and Yamada, Y. (1999) Perlecan is essential for cartilage and cephalic development. Nat. Genet., 23, 354-358.
17. Costell, M., Gustafsson, E., Aszodi, A., Morgelin, M., Bloch, W., Hunziker, E., Addicks, K., Timpl, R. and Fassler, R. (1999) Perlecan maintains the integrity of cartilage and some basement membranes. J. Cell Biol., 147, 1109-1122.
18. Aberfeld, D.C., Hinterbuchner, L.P. and Schneider, M. (1965) Myotonia, dwarfism, diffuse bone disease and unusual ocular and facial abnormalities (a new syndrome). Brain, 88, 313-322.
19. Giedion, A., Boltshauser, E., Briner, J., Eich, G., Exner, G., Fendel, H., Kaufmann, L., Steinmann, B., Spranger, J. and Superti-Furga, A. (1997) Heterogeneity in Schwartz-Jampel chondrodystrophic myotonia. Eur. J. Pediatr., 156, 214-223.
20. Spranger, J., Hall, B.D., Hane, B., Srivastava, A. and Stevenson, R.E. (2000) Spectrum of Schwartz-Jampel syndrome includes micromelic chondrodysplasia, kyphomelic dysplasia, and Burton disease. Am. J. Med. Genet., 94, 287-295.
21. Nicole, S., Davoine, C.S., Topaloglu, H., Cattolico, L., Barral, D., Beighton, P., Hamida, C.B., Hammouda, H., Cruaud, C., White, P.S. et al. (2000) Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat. Genet., 26, 480-483.
22. Stum, M., Davoine, C.S., Vicart, S., Guillot-Noel, L., Topaloglu, H., Carod-Artal, F.J., Kayserili, H., Hentati, F., Merlini, L., Urtizberea, J.A. et al. (2006) Spectrum of HSPG2 (perlecan) mutations in patients with Schwartz-Jampel syndrome. Hum. Mutat., 27, 1082-1091.
23. Schulze, B., Mann, K., Battistutta, R., Wiedemann, H. and Timpl, R. (1995) Structural properties of recombinant domain III-3 of perlecan containing a globular domain inserted into an epidermal-growth-factor-like motif. Eur. J. Biochem., 231, 551-556.
24. Voziyanov, Y., Konieczka, J.H., Stewart, A.F. and Jayaram, M. (2003) Stepwise manipulation of DNA specificity in Flp recombinase: progressively adapting Flp to individual and combinatorial mutations in its target site. J. Mol. Biol., 326, 65-76.
25. Brown, J.C., Sasaki, T., Gohring, W., Yamada, Y. and Timpl, R. (1997) The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur. J. Biochem., 250, 39-46.
26. Costell, M., Mann, K., Yamada, Y. and Timpl, R. (1997) Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides. Eur. J. Biochem., 243, 115-121.
27. Valera, A., Perales, J.C., Hatzoglou, M. and Bosch, F. (1994) Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism. Hum. Gene Ther., 5, 449-456.
28. Schwarze, U., Starman, B.J. and Byers, P.H. (1999) Redefinition of exon 7 in the COL1A1 gene of type I collagen by an intron 8 splice-donor-site mutation in a form of osteogenesis imperfecta: Influence of intron splice order on outcome of splice-site mutation. Am. J. Hum. Genet., 65, 336-344.
29. Shannon, M.B., Patton, B.L., Harvey, S.J. and Miner, J.H. (2006) A hypomorphic mutation in the mouse laminin alpha5 gene causes polycystic kidney disease. J. Am. Soc. Nephrol., 17, 1913-1922.
30. Arikawa-Hirasawa, E., Wilcox, W.R. and Yamada, Y. (2001) Dyssegmental dysplasia, Silverman-Handmaker type: Unexpected role of perlecan in cartilage development. Am. J. Med. Genet., 106, 254-257.
31. Kvist, A.J., Johnson, A.E., Morgelin, M., Gustafsson, E., Bengtsson, E., Lindblom, K., Aszodi, A., Fassler, R., Sasaki, T., Timpl, R. et al. (2006) Chondroitin sulfate perlecan enhances collagen fibril formation. Implications for perlecan chondrodysplasias. J. Biol. Chem., 281, 33127-33139.
32. Stickens, D., Behonick, D.J., Ortega, N., Heyer, B., Hartenstein, B., Yu, Y., Fosang, A.J., Schorpp-Kistner, M., Angel, P. and Werb, Z. (2004) Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development, 131, 5883-5895.
33. Vu, T.H., Shipley, J.M., Bergers, G., Berger, J.E., Helms, J.A., Hanahan, D., Shapiro, S.D., Senior, R.M. and Werb, Z. (1998) MMP-9/ gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell, 93, 411-422.
34. Amizuka, N., Davidson, D., Liu, H., Valverde-Franco, G., Chai, S., Maeda, T., Ozawa, H., Hammond, V., Ornitz, D.M., Goltzman, D. et al. (2004) Signalling by fibroblast growth factor receptor 3 and parathyroid hormone-related peptide coordinate cartilage and bone development. Bone, 34, 13-25.
35. West, L., Govindraj, P., Koob, T.J. and Hassell, J.R. (2006) Changes in perlecan during chondrocyte differentiation in the fetal bovine rib growth plate. J. Orthop. Res., 24, 1317-1326.
36. SundarRaj, N., Fite, D., Ledbetter, S., Chakravarti, S. and Hassell, J.R. (1995) Perlecan is a component of cartilage matrix and promotes chondrocyte attachment. J. Cell Sci., 108 (Pt 7), 2663-2672.
37. Govindraj, P., West, L., Smith, S. and Hassell, J.R. (2006) Modulation of FGF-2 binding to chondrocytes from the developing growth plate by perlecan. Matrix Biol., 25, 232-239.
38. Dagoneau, N., Scheffer, D., Huber, C., Al-Gazali, L.I., Di Rocco, M., Godard, A., Martinovic, J., Raas-Rothschild, A., Sigaudy, S., Unger, S. et al. (2004) Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. Am. J. Hum. Genet., 74, 298-305.
39. Olney, R.C., Bukulmez, H., Bartels, C.F., Prickett, T.C., Espiner, E.A., Potter, L.R. and Warman, M.L. (2006) Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J. Clin. Endocrinol. Metab., 91, 1229-1232.
40. Pfeifer, A., Aszodi, A., Seidler, U., Ruth, P., Hofmann, F. and Fassler, R. (1996) Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. Science, 274, 2082-2086.
41. Zhou, Z., Wang, J., Cao, R., Morita, H., Soininen, R., Chan, K.M., Liu, B., Cao, Y. and Tryggvason, K. (2004) Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res., 64, 4699-4702.
42. Morita, H., Yoshimura, A., Inui, K., Ideura, T., Watanabe, H., Wang, L., Soininen, R. and Tryggvason, K. (2005) Heparan sulfate of perlecan is involved in glomerular filtration. J. Am. Soc. Nephrol., 16, 1703-1710.
43. Datta, M.W., Hernandez, A.M., Schlicht, M.J., Kahler, A.J., Degueme, A.M., Dhir, R., Shah, R.B., Farach-Carson, M.C., Barrett, A. and Datta, S. (2006) Perlecan, a candidate gene for the CABP locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol. Cancer, 5, 9.
44. Mongiat, M., Sweeney, S.M., San Antonio, J.D., Fu, J. and Iozzo, R.V. (2003) Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem., 278, 4238-4249.
45. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W. and Roder, J.C. (1993) Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc. Natl Acad. Sci. USA, 90, 8424-8428.
46. Balint, E., Szabo, P., Marshall, C.F. and Sprague, S.M. (2001) Glucose-induced inhibition of in vitro bone mineralization. Bone, 28, 21-28.
47. Ballanti, P., Minisola, S., Pacitti, M.T., Scarnecchia, L., Rosso, R., Mazzuoli, G.F. and Bonucci, E. (1997) Tartrate-resistant acid phosphate activity as osteoclastic marker: Sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry. Osteoporos Int., 7, 39-43.
48. Aszodi, A., Chan, D., Hunziker, E., Bateman, J.F. and Fassler, R. (1998) Collagen II is essential for the removal of the notochord and the formation of intervertebral discs. J. Cell Biol., 143, 1399-1412.